NCT06060886View on ClinicalTrials.gov

Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

244

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

December 31, 2025

Conditions
SchizophreniaTreatment-resistant SchizophreniaSide EffectLipid Metabolism DisordersDiabetesNAFLDPsychosis
Interventions
DRUG

Aripiprazole

Oral dose range 5-30 mg/day (100 mg- 600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence.

DRUG

Paliperidone

Oral dose range 3-12 mg/day (150mg-600 CPZeq). Long -acting injectables will be highly recommended in order to certify adherence

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Consorcio Centro de Investigación Biomédica en Red (CIBER)

OTHER_GOV